Pdb15 - Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors: Systematic Literature Review and Indirect Comparisons

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.721
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Dipeptidyl Peptidase-4 (DPP-4; CD26)

Science-Business eXchange
2014English

Pdb12 - Cardiovascular Safety of Empagliflozin Versus Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists: Systematic Literature Review and Indirect Comparisons

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2014English

Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-Lowering Therapies for Three Acute Outcomes

Scientific Reports
Multidisciplinary
2018English

Navigating the Chemical Space of Dipeptidyl Peptidase-4 Inhibitors

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Effectiveness in Clinical Practice Versus Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Clinical Trials for Type 2 Diabetes: Protocol for Systematic Review

BMJ Open
Medicine
2019English

Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases

Drug Metabolism and Disposition
PharmacologyPharmaceutical Science
2018English

Systematic Literature Review of DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Renal Impairment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy